Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine.

Obayashi K, Tasaki M, Jono H, Ueda M, Shinriki S, Misumi Y, Yamashita T, Oshima T, Nakamura T, Ikemizu S, Anan I, Suhr O, Ando Y.

Clin Chim Acta. 2013 Apr 18;419:127-31. doi: 10.1016/j.cca.2013.02.002.

PMID:
23462670
2.

Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.

Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M.

Life Sci. 2013 Dec 18;93(25-26):1017-22. doi: 10.1016/j.lfs.2013.10.031.

PMID:
24211615
3.

Presence of autoantibody against ATTR Val30Met after sequential liver transplantation.

Ando Y, Terazaki H, Haraoka K, Tajiri T, Nakamura M, Obayashi K, Misumi S, Shoji S, Hata K, Nakagawa K, Ishizaki T, Uemoto S, Inomata Y, Tanaka K, Okabe H.

Transplantation. 2002 Mar 15;73(5):751-5.

PMID:
11907422
4.

Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy.

Palha JA, Moreira P, Olofsson A, Lundgren E, Saraiva MJ.

J Mol Med (Berl). 2001;78(12):703-7.

PMID:
11434723
5.

Allele specific expression of the transthyretin gene in swedish patients with hereditary transthyretin amyloidosis (ATTR V30M) is similar between the two alleles.

Norgren N, Hellman U, Ericzon BG, Olsson M, Suhr OB.

PLoS One. 2012;7(11):e49981. doi: 10.1371/journal.pone.0049981.

6.

Transthyretin-related vitreous amyloidosis in different endemic areas.

Kawaji T, Ando Y, Ando E, Sandgren O, Suhr OB, Tanihara H.

Amyloid. 2010 Sep;17(3-4):105-8. doi: 10.3109/13506129.2010.527068.

PMID:
21077797
7.

SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy.

Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, Sekijima Y, Ota K, Shinriki S, Jono H, Ikeda S, Suhr OB, Ando Y.

Clin Chem. 2009 Jun;55(6):1223-7. doi: 10.1373/clinchem.2008.118505.

8.

Antibody therapy for familial amyloidotic polyneuropathy.

Su Y, Jono H, Torikai M, Hosoi A, Soejima K, Guo J, Tasaki M, Misumi Y, Ueda M, Shinriki S, Shono M, Obayashi K, Nakashima T, Sugawara K, Ando Y.

Amyloid. 2012 Jun;19 Suppl 1:45-6. doi: 10.3109/13506129.2012.674075.

PMID:
22506915
9.

CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.

Maia LF, Magalhães R, Freitas J, Taipa R, Pires MM, Osório H, Dias D, Pessegueiro H, Correia M, Coelho T.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):159-67. doi: 10.1136/jnnp-2014-308107.

PMID:
25091367
10.

A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers.

Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, Cederquist K, Jonasson J.

BMC Med Genet. 2010 Sep 14;11:130. doi: 10.1186/1471-2350-11-130.

11.
12.

Deposition of transthyretin amyloid is not accelerated by the same amyloid in vivo.

Wei L, Kawano H, Fu X, Cui D, Ito S, Yamamura K, Ishihara T, Tokuda T, Higuchi K, Maeda S.

Amyloid. 2004 Jun;11(2):113-20.

PMID:
15478467
13.

Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features.

Misu Ki, Hattori N, Nagamatsu M, Ikeda Si, Ando Y, Nakazato M, Takei Yi, Hanyu N, Usui Y, Tanaka F, Harada T, Inukai A, Hashizume Y, Sobue G.

Brain. 1999 Oct;122 ( Pt 10):1951-62.

14.

Multi-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients.

Susuki S, Ando Y, Sato T, Nishiyama M, Miyata M, Suico MA, Shuto T, Kai H.

Amyloid. 2008 Jun;15(2):108-16. doi: 10.1080/13506120802006013.

PMID:
18484337
15.

Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant.

Terazaki H, Ando Y, Fernandes R, Yamamura K, Maeda S, Saraiva MJ.

Lab Invest. 2006 Jan;86(1):23-31.

16.

Amyloidogenic transthyretin Val30Met homozygote showing unusually early-onset familial amyloid polyneuropathy.

Tojo K, Sekijima Y, Machida K, Tsuchiya A, Yazaki M, Ikeda S.

Muscle Nerve. 2008 Jun;37(6):796-803. doi: 10.1002/mus.21028.

PMID:
18506713
17.

Impact of serotonin transporter and catechol-O-methyl transferase genes polymorphism on gastrointestinal dysfunction in Swedish and Japanese familial amyloidotic polyneuropathy patients.

Obayashi K, Olsson M, Anan I, Ueda M, Nakamura M, Okamoto S, Yamashita T, Miida T, Ando Y, Suhr OB.

Clin Chim Acta. 2008 Dec;398(1-2):10-4. doi: 10.1016/j.cca.2008.07.033.

PMID:
18760272
18.

Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, Hayashi M, Yamamoto M, Mukai E, Nakamura T, Katsuno M, Hattori N, Sobue G.

J Neurol Sci. 2009 Dec 15;287(1-2):178-84. doi: 10.1016/j.jns.2009.07.028.

PMID:
19709674
19.

[Familial amyloid polyneuropathy: clinicopathological aspects].

Koike H, Sobue G.

Brain Nerve. 2014 Jul;66(7):749-62. Japanese.

PMID:
24998820
20.

Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation.

Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, Takeda K, Okajima H, Asonuma K, Hara R, Tanihara H, Ando Y, Inomata Y.

Surg Today. 2011 Sep;41(9):1211-8. doi: 10.1007/s00595-010-4488-5.

PMID:
21874417
Items per page

Supplemental Content

Support Center